



Statistical challenges and opportunities in ICH M13A

Helmut Schütz

Institute of Medical Statistics of the
Medical University of Vienna



2.1.1 Study Population

Subjects should be at least 18 years of age and preferably have a Body Mass Index between 18.5 and 30.0 kg/m². [...] Subjects should preferably be non-nicotine users [...]

- No concerns about extrapolating to patients < 18 years.
- No concerns about extrapolating to obese patients (in the U.S. ~42% of the adult population).
- No concern about extrapolating to 23% of adults smoking tobacco.

If a drug product is intended for use in both sexes, it is recommended the study include **male and female subjects**.

- Concerns about a Sex-by-Formulation interaction, i.e., questioning extrapolating from a study performed in either sex to the general population?

Meta-study (235 mixed-sex datasets)


185 datasets passing BE

n \tilde{x} 30 (12 – 117)

$f_{\text{♂}}$ \tilde{x} 52.9% (31.9 – 87.5%)

$f_{\text{♀}}$ \tilde{x} 47.1% (12.5 – 68.1%)


- No evidence that medians of subgroups differ (i.e., notches of box plots overlap).
- Similar within-subject CV of males (\tilde{x} 12.53%) and females (\tilde{x} 12.61%).



Meta-study (235 mixed-sex datasets)

185 datasets passing BE

- Difference in PEs of males and females $> \pm 20\%$ in 3.24% of datasets.
- Difference in PEs of males and females $\leq \pm 10\%$ in 77.8% of datasets.
- Discordant Qualitative Interaction in 1.62% of datasets.




Meta-study (235 mixed-sex datasets)

185 datasets passing BE

- Significant ($p < 0.1$)
 $S \times F$ interaction in 12.4%
of datasets.

Confirmed conclusions
of González-Rojano
et al. 2019

“ There is no evidence to
require studies in both
sex groups, combined
or separately.



2.2.3.5 Multi-Group Design Studies

BE should be determined based on the overall treatment effect in the whole study population. In general, the assessment of BE in the whole study population should be done without including the Group by Treatment interaction term in the model [...] However, the appropriateness of the statistical model should be evaluated to account for the multi-group nature of the BE study. **Applicants should evaluate** potential for heterogeneity of treatment effect across groups, i.e., **Group by Treatment interaction**. If the Group by Treatment interaction is **significant**, this should be reported and the **root cause** of the Group by Treatment interaction **should be investigated** to the extent possible.

2.2.3.5 cont'd

Substantial differences in the treatment effect for PK parameters across groups should be evaluated. Further analysis and interpretation may be warranted in case heterogeneity across groups is observed.

- Is assessment of a Group by Treatment interaction mandatory?
- Significance level 0.1?
- Which difference might be 'substantial'?

2.2.3.1 General Considerations

The statistical analysis should **take into account sources of variation that can be reasonably assumed to have an effect on the response variable.**

Crossover models

Interaction model (I)

$Y \sim \text{Group, Sequence, Subject}(\text{Group} \times \text{Sequence}),$
 $\text{Period}(\text{Group}), \text{Group} \times \text{Sequence}, \text{Treatment},$
 $\text{Group} \times \text{Treatment}$

Group model (II)

$Y \sim \text{Group, Sequence, Subject}(\text{Group} \times \text{Sequence}),$
 $\text{Period}(\text{Group}), \text{Group} \times \text{Sequence}, \text{Treatment}$

Conventional (III)

$Y \sim \text{Sequence, Subject}(\text{Sequence}), \text{Period}, \text{Treatment}$


In the interaction model (I) unbiased estimate of the treatment effect not possible!

10⁵ simulated studies ($n_1 = n_2 = 24$)

No Group by Treatment interaction:

$$\text{GMR}_1 = \text{GMR}_2 = 1.0000$$

- Significant $G \times T$ interaction in 10.01% of simulated studies.
- At the level of the test → **false positives!**




10⁵ simulated studies ($n_1 = n_2 = 24$)



True Group by Treatment interaction:

GMR₁ = 0.9000, GMR₂ = 1.1111
(pooled GMR 1.0000)

- Significant $G \times T$ interaction in 46.64% of simulated studies.
- As expected, high above the false positive rate.
- But: In 53.36% the true $G \times T$ interaction is **not** detected!



Meta-study (319 datasets AUC, 322 C_{max})



$G \times T$ interaction ‘detected’ at approximately the level of the test; in well-controlled trials likely false positives.

Conclusions

- No empiric evidence that extrapolation of results from studies in healthy subjects (in either sex...) to the patient population is problematic
- Inclusion of a Group-term may substantially compromise power
- Impossible to detect a true Group-by-Treatment by statistics, i.e., subsequent ‘investigation of a root cause’ is futile

The combination of some data and an aching desire for an answer does not ensure that a reasonable answer can be extracted from a given body of data.

John W. Tukey

A mathematician is a blind man in a dark room looking for a black cat which isn't there.
attr. to Charles Darwin

Statistical challenges (!) and opportunities (?) in ICH M13A

Thank You!



Helmut Schütz

Institute of Medical Statistics



MEDICAL UNIVERSITY
OF VIENNA

1090 Vienna, Austria

helmut.schuetz@meduniwien.ac.at

BEBAC

1070 Vienna, Austria

helmut.schuetz@bebac.at

»Λόγον ἔχεις;« »ἔχω.« »τί οὖν οὐ χρᾶ;«

References

1. Chen M-L, Lee S-C, Ng M-J, Schuirmann DJ, Lesko LJ, Williams RL. *Pharmacokinetic analysis of bioequivalence trials: Implications for sex-related issues in clinical pharmacology and biopharmaceutics*. Clin Pharm Ther. 2000; 68(5): 510–21. <https://doi.org/10.1067/mcp.2000.111184>.
2. Koren G, Nordeng H, MacLeod S. *Gender Differences in Drug Bioequivalence: Time to Rethink Practices*. Clin Pharm Ther. 2013; 93(3): 260–2. <https://doi.org/10.1038/clpt.2012.233>.
3. Alosch M, Fritsch K, Huque M, Mahjoob K, Pennello G, Rothmann M, Russek-Chen E, Smith E, Wilson S, Yiu L. *Statistical Considerations on Subgroup Analysis in Clinical Trials*. Stat Pharm Res. 2015; 7(4): 286–304. <https://doi.org/10.1080/19466315.2015.1077726>.
4. Ibarra M, Vázquez M, Fagiolino P. *Sex Effect on Average Bioequivalence*. Clin Ther. 2017; 39(1): 23–33. <https://doi.org/10.1016/j.clinthera.2016.11.024>.
5. Sun W, Schuirmann D, Grosser S. *Qualitative versus Quantitative Treatment-by-Subgroup Interaction in Equivalence Studies with Multiple Subgroups*. Stat Pharm Res. 2022; Early View 31 Oct 2022. <https://doi.org/10.1080/19466315.2022.2123385>.
6. González-Rojano E, Marcotegui J, Ochoa D, Román M, Álvarez C, Gordon J, Abad-Santos F, García-Arieta A. *Investigation on the Existence of Sex-By-Formulation Interaction in Bioequivalence Trials*. Clin Pharm Ther. 2019; 106(5): 1099–112. <https://doi.org/10.1002/cpt.1539>.
7. Ibarra M, Vázquez M, Fagiolino P. *Sex-by-formulation interaction in bioequivalence studies: the importance of formulations and experimental conditions*. Br J Clin Pharmacol. 2019; 85(4): 669–71. <https://doi.org/10.1111/bcp.13829>.
8. González-Rojano E, Abad-Santos F, Gordon J, García-Arieta A. *Response to ‘Sex-by-formulation interaction in bioequivalence studies: the importance of formulations and experimental conditions’ by Ibarra et al*. Br J Clin Pharma-col. 2019; 85(4): 857–8. <https://doi.org/10.1111/bcp.13860>.
9. Glerum PJ, Neef C, Burger DM, Yu Y, Maliepaard M. *Pharmacokinetics and Generic Drug Switching: A Regulator’s View*. Clin Pharmacokin. 2020; 59: 1065–9. <https://doi.org/10.1007/s40262-020-00909-8>.
10. Benet LZ. *Why Do Bioequivalence Studies in Healthy Volunteers?* 1st MENA Regulatory Conference on Bioequivalence, Biowaivers, Bioanalysis and Dissolution. Amman, Jordan, 23 September 2013. <http://www.rbbbd.com/pdf/presentations/Leslie%20Z%20Benet/lecture%201%20Why%20Do%20Bioequivalence%20Studies%20%20in%20Healthy%20Volunteers.pdf>.
11. Bolton S, Bon C. *Pharmaceutical Statistics. Practical and Clinical Applications*. New York: informa healthcare; 5th edition 2010. p. 629.
12. Bae K-S, Kang S-H. *Bioequivalence data analysis for the case of separate hospitalization*. Transl Clin Pharmacol. 2017; 25(2): 93–100. <https://doi.org/10.12793/tcp.2017.25.2.93>.
13. Schütz H. *Group ‘Effect’. To Pool or Not to Pool?* April 19, 2023. <https://bebac.at/articles/Group-Effect.phtml>.